Mechanisms of Refractory Hypertension (High and Low Salt Diet)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02357017|
Recruitment Status : Recruiting
First Posted : February 6, 2015
Last Update Posted : September 5, 2017
|Condition or disease||Intervention/treatment||Phase|
|Hypertension||Dietary Supplement: NaCl tablets||Not Applicable|
We are proposing a unique phenotype of antihypertensive treatment failure that we refer to as refractory HTN. We have come to feel that while resistant (RHTN) represents a broad phenotype with multiple and overlapping etiologies of treatment resistance, there is a unique subset of patients who never achieve BP control in spite of maximal therapy. In a recently published retrospective analysis of our clinic experience, we found that patients with refractory HTN comprised about 10% of patients referred to us for RHTN.
A large number of intervention studies have verified the benefit of dietary salt restriction to reduce BP. We made such an assessment in a prospective, randomized, cross-over comparison of high- and low salt diets in 12 patients with confirmed RHTN. The average reduction in BP going from high to the low salt diet was 23/10 mmHg in the clinic and 20/10 mmHg during 24-hr ambulatory BP monitoring. These dramatic results demonstrated that patients with RHTN are exquisitely salt-sensitive and highlight the degree of BP reduction that can be accomplished with meaningful salt restriction. However, we are proposing the novel hypothesis that refractory HTN is mechanistically unique from RHTN in that it is not secondary to recalcitrant fluid retention.
Determining an association between dietary salt restriction and severity of obstructive sleep apnea (OSA) would potentially help us to find new therapies guided towards achieving better control of BP in patients with refractory HTN. We will investigate the effect of dietary salt intake on severity of OSA vascular function in patients with refractory HTN by doing vascular studies (pulse wave analysis/velocity, calculating thoracic impedance)).
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Official Title:||Mechanisms of Refractory Hypertension (High and Low Salt Diet)|
|Study Start Date :||February 2015|
|Estimated Primary Completion Date :||January 2019|
|Estimated Study Completion Date :||January 2019|
Active Comparator: Low salt diet
The low-salt meals will be formulated to provide 50 mmol of sodium per day. Two diets with different caloric amounts (2000 or 2500) will be available.
Dietary Supplement: NaCl tablets
Active Comparator: High salt diet
High dietary salt intake, NaCl tablets (6 grams/day) will added to the subject's study diet in order to increase dietary sodium intake to >250 mmol/day.
Dietary Supplement: NaCl tablets
- Change in 24-hour ambulatory systolic blood pressure (BP). [ Time Frame: baseline to 4 weeks ]The mean change in blood pressure for each group after receiving 4 weeks of either a low salt diet compared to High dietary salt intake. The low-salt meals will be formulated to provide 50 mmol of sodium per day. Two diets with different caloric amounts (2000 or 2500) will be available. High dietary salt intake, NaCl tablets (6 grams/day) will added to the subject's study diet in order to increase dietary sodium intake to >250 mmol/day.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02357017
|Contact: Felice Cookemail@example.com|
|United States, Alabama|
|David A. Calhoun, MD||Recruiting|
|Birmingham, Alabama, United States, 35214|
|Contact: David A. Calhoun, MD 205-934-4633 firstname.lastname@example.org|
|Principal Investigator:||David A. Calhoun, MD||Cardiology Department - University of Alabama at Birmingham|